Movetis aims to become a successful European speciality GI company whose proprietary, innovative drugs improve the treatment of gastrointestinal (GI) diseases with a high unmet medical need, to the benefit of patients.
Movetis was founded in Belgium in November 2006 as a spin-out of Johnson & Johnson, and is publicly listed since its IPO in December 2009.
 
Movetis has a broad GI portfolio, with one product approved in the EEA: prucalopride, for the indication “symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief”, two products in Phase II development (M0002 and M0003) and two prioritised compounds in preclinical development. In addition, Movetis has rights to a large library of qualified lead compounds with potential for development in different GI indications and access to know how for compounds in secretory diarrhoea.